13 completed, 5 active not recruiting, 3 not yet recruiting, 3 recruiting. 15 Phase 1, 9 Phase 2, 5 Phase 3, 2 Not applicable, 1 Phase 4.
Follow PharmaEssentia: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Ropeg-Interferon in People With Polycythemia Vera Ropeginterferon - Polycythemia Vera (PV), JAK2 Mutation | Phase 2 | Not yet recruiting | Memorial Sloan Kettering Cancer Center | 55 | 2026-10-30 | 2026-10-21 |
| A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in MDS/AML With TP53 Mutations ropeginterferon alfa- 2b, Azacitidine (AZA) - Ropeginterferon, Alfa-2b | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2026-10-27 | 2026-10-16 |
| Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 2 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 35 | 2026-09-29 | 2026-05-06 |
| Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis ropeginterferon alfa- 2b, Ruxolitinib - Myelofibrosis | Phase 1 | Recruiting | University of Utah | 15 | 2026-08-21 | 2026-10-19 |
| Standardized Documentation and Assessments for Polycythemia Vera: A Quality Improvement Initiative Standardized progress note - Polycythemia Vera | Not applicable | Not yet recruiting | Massachusetts General Hospital | 32 | 2026-08-05 | 2026-07-29 |
| Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera Ropeginterferon alfa-2b, Phlebotomy and aspirin - Polycythemia Vera, Myeloproliferative Neoplasm | Phase 4 | Withdrawn | PharmaEssentia | 2026-08-01 | 2026-07-31 | |
| Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL) Ropeginterferon alfa-2b - Cutaneous T Cell Lymphoma | Phase 1 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 38 | 2025-08-27 | 2026-04-01 |
| P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk Ropeginterferon alfa-2b, Placebo - Primary Myelofibrosis, Myeloproliferative Neoplasm | Phase 3 | Active not recruiting | PharmaEssentia | 160 | 2025-07-18 | 2026-08-13 |
| Phase I Open-Label Study of P1101 Followed by P1801 in Advanced Solid Tumors Sequential use of P1101 and P1801 - Advanced Solid Tumors | Phase 1 | Enrolling by invitation | PharmaEssentia | 54 | 2025-04-21 | 2025-07-08 |
| A Phase I PK/PD Study of PEG-MetHuG-CSF (P2203) in Healthy Volunteers PEG-MetHuG-CSF, Neulasta (Amgen) - PK in Healthy Volunteers | Phase 1 | Completed | PharmaEssentia | 30 | 2024-08-19 | 2025-06-29 |
| HLA-A*02:01 Allele Frequency and the NY-ESO-1 Expression Status in Cancer Patients in Taiwan Solid Tumor Malignancy | Terminated | PharmaEssentia | 485 | 2023-03-14 | 2026-07-22 | |
| A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-Infection Ursodeoxycholic acid, Ropeginterferon alfa-2b, Tenofovir Alafenamide - Hepatitis D | Phase 2 | Unknown | National Taiwan University Hospital | 30 | 2023-02-24 | 2022-12-29 |
| A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV P1101 (Ropeginterferon alfa-2b-njft), Ropeginterferon alfa-2b-njft (P1101) - Polycythemia Vera | Phase 3 | Active not recruiting | PharmaEssentia | 111 | 2022-10-26 | 2025-08-13 |
| A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET Ropeginterferon alfa-2b-njft (P1101) - Essential Thrombocythemia | Phase 2 | Active not recruiting | PharmaEssentia | 91 | 2022-09-29 | 2025-08-13 |
| The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection P1101 + Nivolumab + Entecavir - Chronic Hepatitis B Infection, Chronic Hepatitis D Infection | Phase 1 | Completed | PharmaEssentia | 20 | 2022-08-17 | 2026-06-10 |
| A Multi-Center Study to Evaluate the Efficacy and Safety of KX01 Ointment 1% on Actinic Keratosis on Face or Scalp KX01 ointment 1%, Placebo - Actinic Keratosis | Phase 3 | Completed | PharmaEssentia | 108 | 2021-12-21 | 2024-04-19 |
| Safety Evaluation of KX01 Ointment 1% in Japanese Healthy Male Subjects KX01 ointment 1%, Placebo ointment - Healthy Volunteer | Phase 1 | Completed | PharmaEssentia | 20 | 2021-11-16 | 2022-02-18 |
| A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU Ropeginterferon alfa-2b - Polycythemia Vera | Phase 2 | Active not recruiting | PharmaEssentia | 49 | 2021-10-08 | 2025-08-03 |
| Comparing P1101 to Entecavir in Patients With HBeAg(-) Hepatitis B Under Long-term Nucleos(t)Ide Analogue Therapy Ropeginterferon alfa-2b, Entecavir - Chronic Hepatitis B Virus Infection | Not applicable | Unknown | National Taiwan University Hospital | 90 | 2021-05-04 | 2022-12-27 |
| The Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection P1101 + Ribavirin - Hepatitis C, Chronic | Phase 1 | Completed | PharmaEssentia | 17 | 2020-11-26 | 2022-08-30 |
Showing 20 of 31. Sign in to see all of them.
Myeloproliferative Disorders (5) · Polycythemia Vera (5) · Thrombocythemia, Essential (3) · Hepatitis B, Chronic (2) · Hepatitis C, Chronic (2) · Primary Myelofibrosis (2) · Thrombocytosis (2) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Dermatitis, Phototoxic (1) · Hepatitis B (1) · Hepatitis C (1) · Hepatitis D (1) · Keratosis, Actinic (1) · Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (1)
Paclitaxel (3) · Nivolumab (2) · Ribavirin (2) · entecavir (2) · peginterferon alfa-2a (2) · peginterferon alfa-2b (2) · Aspirin (1) · Azacitidine (1) · Biopsy (1) · Phlebotomy (1) · RE1-silencing transcription factor (1) · Specimen Handling (1) · Ursodeoxycholic Acid (1) · anagrelide (1) · pegfilgrastim (1)
Taiwan (16) · United States (9) · Canada (5) · China (4) · Japan (4) · Australia (3) · South Korea (3) · Hong Kong (2) · New Zealand (2) · Singapore (2) · Jordan (1) · United Kingdom (1)
David Cutler, MD (2) · Pei-Jer Chen (2) · Toshiaki Sato, MD/PhD (2) · Chun-Jen Liu (1) · Craig Zimmerman, PhD (1) · Hisakuni Sekino (1) · Huang Yi-Wen, MD/PhD (1) · Jackson Christopher, MD (1) · Jason Lickliter, MD (1) · Jayastu Senapati, MD (1) · Jin-Bon Hong, M.D. (1) · Jingjing Zhang (1) · Kuan-Chiao Tseng, MD, Sc.D. (1) · Ole Zagrijtschuk, MD, PhD (1) · Oleh Zagrijtschuk, MD, PhD (1)
PMID 40313042, PMID 33725322, PMID 34386602, PMID 34907578, PMID 35924546, PMID 37129584, PMID 37344895, PMID 37492633, PMID 40330782, PMID 41193116, PMID 42306077